Ask about Cagrilintide
Get a grounded answer across clinical evidence, community patterns, and risks.
Cagrilintide
Long-acting amylin receptor agonist
Mechanism of Action
Activates amylin receptors, promoting satiety, slowing gastric emptying, and potentially preserving beta-cell function.
Currently in Phase 3 clinical trials, cagrilintide is a long-acting amylin receptor agonist that promotes satiety and slows gastric emptying. The CagriSema combination (cagrilintide + semaglutide) has shown superior weight loss compared to semaglutide alone across 3 clinical trials, earning an A clinical grade. Appetite suppression was the most frequently noted outcome (247 mentions, 119 unique individuals), while self-reported weight loss sentiment was 81% positive or neutral (n=141).
Reported Outcomes
Clinical grade reflects published research; Community grade reflects user reports (n=3,092).
Reduced hunger and food cravings
Acting as a long-acting amylin analogue, cagrilintide targets homeostatic and hedonic brain regions (such as the dorsal vagal complex) to reduce food intake and induce satiety.
Reduction in body weight
Cagrilintide monotherapy demonstrates weight loss efficacy comparable to semaglutide and liraglutide in clinical trials. The combination of cagrilintide and semaglutide (CagriSema) has shown superior weight loss compared to semaglutide alone and placebo.
Effects on sleep quality
Changes in energy and fatigue levels
Effects on mood and cognitive function
Changes in muscle vs fat ratio
Improved glycemic control and insulin sensitivity
As an amylin analogue, cagrilintide may contribute to glycemic control by slowing gastric emptying and suppressing post-prandial glucagon, though direct monotherapy glucose metrics are less emphasized in the provided text compared to weight effects.
Effects on heart health markers
Who Discusses Cagrilintide
From community reports with demographic data.
Gender
n=106
Age Distribution (limited data)
n=44
Side Effects
Based on 176 user reports (n=176). Frequency indicates how often each was mentioned.
Common (>5%)
Uncommon (1-5%)
Risks & Warnings
Important safety considerations based on clinical data and community reports.
Pancreatitis
Rare but serious. Stop medication and seek care for severe persistent abdominal pain.
Thyroid Concerns
GLP-1 agonists carry a boxed warning for thyroid C-cell tumors in rodents. Contraindicated in MEN2 or personal/family history of MTC.
Gallbladder Issues
Rapid weight loss increases gallstone risk. Report severe abdominal pain to healthcare provider.
Hypoglycemia Risk
Risk increases when combined with insulin or sulfonylureas. Monitor blood sugar carefully.
Psychiatric Effects
Monitor for mood changes. Report any concerning psychiatric symptoms to healthcare provider.
Muscle Loss
Rapid weight loss may include muscle. Adequate protein intake and resistance training recommended.
Gastrointestinal Issues
GI side effects are the most commonly reported. Usually improve over time with slow titration.
Injection Site Reactions
Local reactions are common and usually mild. Rotate injection sites.
Dosing
Standard Protocol
- Starting Dose
- 0.3mg weekly (research protocols)
- Titration
- Titrate over weeks to target dose
- Half-life
- ~7 days
- Administration
- Subcutaneous injection, once weekly
Community Dosing Patterns
Based on 228 mentions
Community-reported patterns, not medical advice.
Pricing
Research-grade reference pricing for 5mg vial. Prices vary by vendor and quantity. Research chemicals require self-mixing and lack medical oversight. Shipping is not included.
We do not list vendors. Prices are aggregated from community reports and should be treated as rough ranges.
US Research Grade
Single small vial from US domestic vendors
US Research (Bulk)
Per-dose equivalent when buying larger US vials
China Research
Per-vial when buying 10-pack from Chinese vendors
Research
Key Studies
Int J Mol Sci (2024)
Diseases (2025)
NPJ Metab Health Dis (2024)
J Clin Med (2025)
Commonly Stacked With
From community members' documented stacks involving Cagrilintide.
Switching Patterns
Based on 307 discussions about switching to or from Cagrilintide.
→ Switching FROM
Users who switched to Cagrilintide
← Switching TO
Users who switched from Cagrilintide